About this trial
The goal of this clinical trial is to learn if ESP block is safe and effective for perioperative analgesia in patients undergoing liver transplant. The main question it aims to answer are Is ESP block safe and has a minimum side effects, like hematoma? Is it effective for perioperative analgesia? Researchers will compare the results to a group of patients who underwent liver transplants without any regional anaesthesia techniques.
Participants will receive bilateral thoracic ESP block on the day of the transplantation with a subsequent bilateral catheterization.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
impaired liver function - cirrhosis or chronic liver disease with the development of hypocoagulation (APTT > 35 sec, INR > 1.5), thrombocytopenia, patients requiring major abdominal surgery, age > 18 years, written consent to participate in the study was obtained
Disqualifiers
Platelet count <50x109, failed ESP catheterization unilateral or bilateral, failed epidural anesthesia attempt, history of allergy or hypersensitivity to local anesthetics, hepatopulmonary syndrome, patients on mechanical ventilation before surgery, patients on CRRT before surgery, refusal to participate in the study
Trial design
Single group
Treatments tested in this trial
Erector Spinae Plane Block using 0.2% ropivacaine
Procedure/SurgeryBilateral thoracic ESP block on the day of the transplantation with a subsequent catheterization will be suggested for the patients. In case of their written consent for the participation in the study this procedure will be performed on the day of the operation. 0.2% ropivacaine is going to be used throughout all the perioperative period.
Treatment groups
Trial outcomes
Primary outcomes
Pain reduction postoperative
Pain assessment with scores
Opioid reduction intraoperatively
The amount of intraoperative fentanyl
Need for opioids postoperatively
Need for opioids postoperatively
Sponsors and contacts
Click on the lead sponsor to view all of their trials.